Table II.

NOD-IL-4 splenocytes inhibit the development of insulitisa

GroupDonor Splenocytes FromRecipientsTotal No. of Islets/GroupGrade of Insulitis (%)Insulitis Score
0123
ADiabeticNOD77123926231.6
DiabeticNOD-IL-4486529600.41b
BGAD65-stimulatedNOD75151232412.0
GAD65-stimulatedNOD-IL-48969191110.45b
CDiabetic+ NODNOD.scid48152945111.5
Diabetic+ NOD-IL-4NOD-scid8848331900.71**
DGAD65-stimulated-NOD+ diabeticNOD.scid41182435231.6
GAD65-stimulated-NOD-IL-4+ diabeticNOD.scid4769191300.45**
  • a Pancreatic islets were scored for insulitis by hematoxylin and eosin staining 7 days following adoptive transfer of 5 × 106 recently diabetic NOD splenocytes (group A); 1.5 × 107 GAD65 stimulated NOD splenocytes (group B); 3 × 106 diabetic plus 1.5 × 107 NOD or NOD-IL-4 (group C); or 1 × 107 GAD65 stimulated plus 5 × 106 recently diabetic NOD splenocytes (group D).

  • b p < 0.0001; ** p < 0.01 (χ2 test).